Company Analysis Fusion Pharmaceuticals Inc.
1. Summary
Advantages
- Price (21.55 $) is less than fair price (24.44 $)
- The stock's return over the last year (0.56%) is higher than the sector average (-31.73%).
Disadvantages
- Dividends (0%) are below the sector average (0.542%).
- Current debt level 13.62% has increased over 5 years from 8.21%.
- The company's current efficiency (ROE=-42.65%) is lower than the sector average (ROE=14.17%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Fusion Pharmaceuticals Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 0% | -20.3% | 7% |
| 90 days | 0% | -34.1% | -3.8% |
| 1 year | 0.6% | -31.7% | 14.7% |
FUSN vs Sector: Fusion Pharmaceuticals Inc. has outperformed the "Healthcare" sector by 32.29% over the past year.
FUSN vs Market: Fusion Pharmaceuticals Inc. has significantly underperformed the market by -14.17% over the past year.
Stable price: FUSN is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: FUSN with weekly volatility of 0.0108% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (21.55 $) is lower than the fair price (24.44 $).
Price not significantly lower than the fair price: The current price (21.55 $) is slightly lower than the fair price by 13.4%.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (63.25).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (90.33).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (2.35) is lower than that of the sector as a whole (18.83).
P/BV vs Market: The company's P/BV (2.35) is lower than that of the market as a whole (9.51).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (252.87) is higher than that of the sector as a whole (32.67).
P/S vs Market: The company's P/S indicator (252.87) is higher than that of the market as a whole (10.25).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-5.22) is lower than that of the sector as a whole (274.42).
EV/Ebitda vs Market: The company's EV/Ebitda (-5.22) is lower than that of the market as a whole (51.38).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 4.33% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (4.33%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-15.75%).
5.4. ROE
ROE vs Sector: The company's ROE (-42.65%) is lower than that of the sector as a whole (14.17%).
ROE vs Market: The company's ROE (-42.65%) is lower than that of the market as a whole (9.57%).
5.5. ROA
ROA vs Sector: The company's ROA (-33.2%) is lower than that of the sector as a whole (1.18%).
ROA vs Market: The company's ROA (-33.2%) is lower than that of the market as a whole (6.63%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (-32.78%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (-32.78%) is lower than that of the market as a whole (11%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.542%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 21.04.2022 | Valliant John Chief Executive Officer |
Sale | 6.01 | 5 541 | 922 |
| 20.04.2022 | Valliant John Chief Executive Officer |
Sale | 6.02 | 2 209 | 367 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
